mouth dissolving tablets

Tablet is the most popular dosage form of all existing dosage forms , but in some cases due to the large size of dosage forms, in case of uncooperative, pediatric and dysphasia patients, it may create  problems, to overcome this , a new form of dosage form is developed, which is known as fast dissolving tablets or mouth dissolving tablets. These dosage forms are also used to attain instant higher concentration of drug in body for immediate actions. Gliclazide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). Fenugreek seed powder was added to this formuation because of  its various pharmacological benefits as well as its self disintegrating property. Mouth dissolving tablets were prepared using direct compression method .Formulations were optimized to develop tablets having minimum possible disintegration time. Tablets were evaluated for hardness, weight variation, friability, wetting time, disintegration time and stability. The main objective of the present research is formulation and evaluation  of mouth dissolving tablets of gliclazide which is an antidiabetic drug ,containing fenugreek seed powder as disintegrating agent.

In the present study, novel co-processed superdisintegrants were developed by solvent evaporation method using crospovidone and croscarmellose sodium in the different ratios (1:1, 1:2 & 1:3) to formulate mouth dissolving tablet formulations of Meloxicam. The poor aqueous solubility of Meloxicam makes its absorption as dissolution rate-limited and thus delay onset of action. Mouth dissolving tablets of Meloxicam were prepared using the above co-processed superdisintegrants and evaluated for different parameters. Effect of co-processed superdisintegrants (such as crospovidone and sodium starch glycolate) on wetting time, disintegrating time, drug content and in-vitro release parameters have been studied. Based on in vitro dispersion time (approximately 19 sec), promising formulation CP1 was tested for in-vitro drug release pattern. Among the designed formulations, the formulation (CP1) containing 4% w/w of co-processed superdisintegrant (1:1 mixture of crospovidone and sodium starch glycolate) found as the best formulation based on drug release characteristics. From this study, it can be concluded that dissolution rate of Meloxicam could be enhanced by tablets containing co-processed superdisintegrant.

  Aceclofenac is a non-steroidal anti-inflammatory, analgesic and antipyretic drug used in the treatment of rheumatic arthritis, post-traumatic pain, masculo-skeletal and joint disorder. Problem with this drug is poor solubility in water hence poor bioavailability after oral administration. The objective of the research work was to develop and evaluate mouth dissolving tablets of Aceclofenac by using sublimation technique. The sublimation technique is used to increase the porosity of the tablets in which camphor was used as subliming agents which in turn forms the porous structure on the surface of tablets after sublimation. Aspartame was used as sweetening agent. The formulated tablets were evaluated for different parameters like weight variation, hardness, friability, drug content, disintegration time, wetting time, water absorption ratio, and In-vitro dissolution studies. Based on the results, formulation F-3 & F-6 containing Crosprovidon and Kyron T-314 10% concentration as superdisintegrants showed the least wetting time of about 17 & 13 sec, disintegration time of 25 & 18 sec and drug release of about 89.13 & 99.14% within 180 sec respectively and was found to be promising and selected as the optimized formulations. From the results, it was concluded that mouth dissolving tablets with improved Aceclofenac dissolution could be prepared by sublimation of tablets containing suitable subliming agent. Key words: Aceclofenac, mouth dissolving tablets, in-vitro, sublimation technique.